Display options
Cite
Brautaset Englund KV, Østby CM, Rolid K, et al. Intravenous iron supplement for iron deficiency in cardiac transplant recipients (IronIC): A randomized clinical trial. J Heart Lung Transplant. 2021;40(5):359-367doi: 10.1016/j.healun.2021.01.1390.
Brautaset Englund, K. V., Østby, C. M., Rolid, K., Gude, E., Andreassen, A. K., Gullestad, L., & Broch, K. (2021). Intravenous iron supplement for iron deficiency in cardiac transplant recipients (IronIC): A randomized clinical trial. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 40(5), 359-367. https://doi.org/10.1016/j.healun.2021.01.1390
Brautaset Englund, Kristine V, et al. "Intravenous iron supplement for iron deficiency in cardiac transplant recipients (IronIC): A randomized clinical trial." The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation vol. 40,5 (2021): 359-367. doi: https://doi.org/10.1016/j.healun.2021.01.1390
Brautaset Englund KV, Østby CM, Rolid K, Gude E, Andreassen AK, Gullestad L, Broch K. Intravenous iron supplement for iron deficiency in cardiac transplant recipients (IronIC): A randomized clinical trial. J Heart Lung Transplant. 2021 May;40(5):359-367. doi: 10.1016/j.healun.2021.01.1390. Epub 2021 Jan 23. PMID: 33612360.
Copy Download .nbib Format: NLM
Share it on

J Heart Lung Transplant. 2021 May;40(5):359-367. doi: 10.1016/j.healun.2021.01.1390. Epub 2021 Jan 23.

Intravenous iron supplement for iron deficiency in cardiac transplant recipients (IronIC): A randomized clinical trial.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

Kristine V Brautaset Englund, Charlotte M Østby, Katrine Rolid, Einar Gude, Arne K Andreassen, Lars Gullestad, Kaspar Broch

Affiliations

  1. Department of Cardiology, Oslo University Hospital, Rikshospitalet, Norway; University of Oslo, Oslo, Norway; K.G. Jebsen Cardiac Research Center and Center for Heart Failure Research, Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address: [email protected].
  2. Department of Cardiology, Oslo University Hospital, Rikshospitalet, Norway.
  3. Department of Cardiology, Oslo University Hospital, Rikshospitalet, Norway; University of Oslo, Oslo, Norway; K.G. Jebsen Cardiac Research Center and Center for Heart Failure Research, Faculty of Medicine, University of Oslo, Oslo, Norway.
  4. Department of Cardiology, Oslo University Hospital, Rikshospitalet, Norway; K.G. Jebsen Cardiac Research Center and Center for Heart Failure Research, Faculty of Medicine, University of Oslo, Oslo, Norway.

PMID: 33612360 DOI: 10.1016/j.healun.2021.01.1390

Abstract

AIMS: Heart transplant recipients have reduced exercise capacity despite preserved graft function. The IronIC trial was designed to test the hypothesis that intravenous iron therapy would improve peak oxygen consumption in these patients.

METHODS AND RESULTS: This randomized, placebo-controlled, double-blind trial was performed at our national center for heart transplantation. One hundred and 2 heart transplant recipients with a serum ferritin <100 µg/liter or 100 to 300 µg/liter, in combination with transferrin saturation of <20%, and hemoglobin level >100 g/liter were enrolled ≥1 year after transplantation. A cardiopulmonary exercise test was performed before administration of the study drug and at 6 months follow-up. The primary endpoint was peak oxygen consumption. Key secondary outcomes included iron status, handgrip strength, quality of life, and safety. Fifty-two patients were randomized to receive ferric derisomaltose 20 mg/kg, and 50 to placebo. The between-group difference in baseline-adjusted peak oxygen consumption was 0.3 ml/kg/min (95% confidence interval -0.9 to 1.4, p = 0.66). In patients with a baseline ferritin <30 µg/liter, peak oxygen consumption was significantly higher in the ferric derisomaltose arm. At 6 months, iron stores were restored in 86% of the patients receiving ferric derisomaltose vs 20% in patients receiving placebo (p < 0.001). Quality of life was significantly better in patients receiving ferric derisomaltose. Twenty-seven adverse events occurred in the intravenous iron group vs 30 in the placebo group (p = 0.39).

CONCLUSION: Intravenous iron treatment did not improve peak oxygen consumption in heart transplant recipients with ferritin <100 µg/liter or 100 to 300 µg/liter in combination with transferrin saturation <20%.

TRIAL REGISTRATION NUMBER: http//www.clinicaltrials.gov identifier NCT03662789.

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Keywords: cardiac transplant; health-related quality of life; heart transplant; iron deficiency; peak oxygen consumption

Publication Types